Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI), a commercial-stage biotechnology company with a primary focus in oncology and hematology, and TopoTarget A/S, today announced that the first patient has been dosed in a National Cancer Institute (NCI)-sponsored Phase 1/2 trial of belinostat in combination with cisplatin, doxorubicin and cyclophosphamide in the first line treatment of advanced or recurrent thymic malignancies. The trial is designed to determine what drug doses can be safely administered together in patients, and to make dose recommendations for future clinical trials. This trial is among the first to test the feasibility of simultaneously administering a histone deacetylase (HDAC) inhibitor, such as belinostat, with common chemotherapy agents such as cisplatin, doxorubicin, and cyclophosphamide, in the first line treatment of advanced or recurrent thymic malignancies. The study is expected to recruit between 30 and 48 evaluable patients.
“We are pleased that the NCI continues to investigate the use of belinostat in the treatment of various cancers”
“We are pleased that the NCI continues to investigate the use of belinostat in the treatment of various cancers,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. “We believe belinostat has the potential to be an effective treatment in combination with existing chemotherapeutic agents for the treatment of thymomas, thymic malignancies, and other cancers.”
Study shows AI can predict prognosis in triple-negative breast cancer